confidential presentation at bioequity, stockholm, may 2013 developing novel antimicrobials against...
TRANSCRIPT
Confidential
Presentation at BioEquity, Stockholm, May 2013
Developing novel antimicrobials against ”difficult to treat” multi drug resistant bacteria
Confidential
Summary – Adenium Biotech
• A spin-out from Novozymes, founded in 2011, strong VC syndicate• Management team with extensive experience, industry
experienced Board of Directors and strong Scientific Advisory Board of KOL´s
• ”First-in-class” Arenicin compounds with potent and selective activity against multi-drug resistant Gram-negative bacteria
- Selection of clinical candidate/initiation of tox/safety in October 2013
- ”First in man” by end of 2014• Funding requirement:
- USD 10 mio to progress through phase I
- USD 25 mio to progress through clinical ”proof of concept” in phase II
2
Confidential
Adenium Biotech ApS• Management:
- Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet, ARTS Biologics
- Søren Neve, PhD, project dir, ex Lundbeck, Novozymes
• Investors:
- Novo Seeds - Sunstone Capital
• Board of Directors:
- Khalid Islam, PhD, ex Arpida, chairman
- Anker Lundmose, MD, ex Novo Nordisk, OSI Pharmaceuticals
- Andreas Segerros, MSc, MBA, Sunstone Capital
- Stephan Christgau, PhD, Novo Seeds - Casper Tind Hansen, MSc, Novo Ventures
- Ejner Bech Jensen, MSc, VP R&D Novozymes A/S
• Scientific advisory board:
- Prof Brad Spellberg, US - Prof David Livermore, UK - Dr Bruce Montgomery, US - Dr Frank Fildes, UK - Prof Matt Cooper, AUS
3
Confidential
Arenicin selection process. Adenium benefits from extensive AMP know how
Variant library generation(~250.000 variants)
~40 AMP’s identified
Several G+ but only one G- identified
> 500 organisms screened for antimicrobial activity
NZ17074
Second variant library (~90.000 variants)
1500 hits but only 10 variants selected
First HitLead
4
Confidential
Medical need for broad spectrum Gram-negative
antimicrobial• Bacteria are rapidly becoming resistant to known antibiotics
- 160.000 patients with nosocomial XDR Gram-negative
infections in 2011 in USA alone
- Carbapenem resistant Klebsiella increased from < 5 % to
29.6% in Italy over 5 years• Increasing resistance even to last and toxic resorts e.g. Colistin• GAIN legislation approved to grant priority review, fast track
status and extend market exclusivity period with 5 years• GAIN pathogens: Acinetobacter, Klebsiella, Pseudomonas and
E. Coli
5
Confidential
Ideal Target Product Profile for multidrug resistant broad spectrum Gram-negative antimicrobial
• Novel mode of action• Bactericidal• Selective and specific• Low frequency of resistance• Active against GAIN pathogens• Drugable
6
Confidential
Arenicin: Unique MoA and broad spectrum Gram-negative activity
• Arenicin is bactericidal with a novel, dual mode of action– Bacterial membrane penetration– Protein synthesis inhibition
• Selective and specific - no hemolytic or cytotoxic activity in mammalian cells
• Very low spontaneous mutational frequency and resistance• Broad spectrum activities against a wide range of XDR Gram-
negative pathogens• Wide therapeutic window. 50 – 100 fold difference between
effective dose and MTD in vivo• 21 AA peptide synthesized by standard solid phase synthesis
7
Confidential
P. aeruginosa incubated with 32 μg/mL AA143. Red arrow shows the membrane disruption. Blue arrow shows release of the cytoplasm.
TEM of P.aeruginosa after incubation with AA143
Arenicin and the cell membrane -MoA
0 16 64 256 1024 40960
5
10
15
20
25
Arcolpip
Extracellular ATP after 10 min
x MIC
Fold
change
Arenicin (Ar), colistin (col), and piperacillin (pip) induced release of ATP from E. coli. Exponential cells were incubated with drug for 10 minutes and ATP measured. y-axis is fold change relative to untreated and x-axis is fold MIC applied.
8
Confidential
Arenicin interferes with the phospholipid homeostasis
9
• MlaC is a periplasmic binding protein maintaining phospholipid homeostasis of the dual cell membrane
• Whole genome sequencing of E. Coli shows only one single L11R amino acid mutation in MlaC correlating well with the very low spontaneous mutational frequency
Confidential
Arenicin shows low potential for resistance development
Organism Isolate ID
Resistance Frequency (4 X MIC)
AA139 AA230
E. coli ATCC 25922≤ 2,50E-12 ≤ 2,50E-12
K. pneumoniae 3083583≤ 1,38E-11 ≤ 1,38E-11
P. aeruginosa ATCC 27853≤ 2,61E-12 ≤ 2,61E-12
A. baumannii 3083835≤ 2,65E-12 ≤ 2,65E-12
10
Confidential
Arenicin is selective and specific for bacteria with low
hemolytic and cytotoxic activity
11
wt
Confidential
# strains AA139 AA230 Ceftazidime Ciprofloxacin Colistin Gentamicin Meropenem Tigecycline
N=325 MIC (µg/ml)
E.coli N=55 1 0.5 >32 >4 0.25 >32 4 0.5
K.pneumonia N=75 4 4 >32 >4 8 >32 >16 4
P.aeruginosa N=75 8 2 >32 >4 2 >32 >16 >8
A.baumanii N=120 2 2 >32 >4 8 >32 >16 4
Arenicin shows favorable efficacy compared to current
treatment optionsMIC90 determinations (MDR strains)
12
Confidential
Arenicin shows good activity in animal models of UTI and
Pneumonia
13
• Arenicin shows good efficacy in the UTI model with ED50 at 1.8 mg/kg in the bladder
• Arenicin shows good efficacy in the Pneumonia model
Confidential
Arenicin is well tolerated with a wide therapeutic window
• Favorable MTD in mini-pigs and mice at 30-50 mg/kg
• No observed adverse effect level (NOAEL) at 30 mg/kg
• Therapeutic window (NOAEL/ED50 bladder) of 75
• Three times longer half-life than Meropenem in mini-pigs
• Well distributed with a high volume of distribution of 900 ml
14
Confidential
Indications Meropenem Colistin ArenicinPneumonia +++ +++ +++Complicated urinary tract infections +++ +++ +++Coverage
XDR E.coli ++ +++ +++XDR P.aeruginosa ++ +++ +++XDR A.baumannii + +++ +++KPC K.pneumonia - +++ +++Colistin G- Bacteria - - +++Administration
Oral no no noIV yes yes yesIT no yes ?
Renal/Hepatic yes yes yesNeurological no yes noHypersensitivity yes yes yes
Bactericidal yes yes yes
Product profiles of Meropenem, Colistin and Arenicin
15
Confidential
Milestone plan
• In vivo efficacy against key pathogens Pseudomonas, Acinetobacter and Klebsiella in pneumonia Completed
• Two leads identified for lead optimization Completed• Clinical candidate selection Oct 2013• IND enabling tox/safety completed Q4 2014• IND filing Q4 2014• First in man initiation Q1 2015• Initiation of clinical ”Proof of Concept” (phase II) Q2 2016• Completion of clinical PoC Q2 2017
16
Confidential
External activities and cost for development of Arenicin in
cUTITask 2013 2014 2015 2016 2017 2018 2019 CostMUSD
Lead candidate selection
Synthesis of 2 kg of cGMP material (Pre clin , phI) 2.0
Fill and finish ( phI ) 0.3
Pre-clinical tox/ safety 0.5
CTA/IND 0.1
Phase I (SAD/MAD) 2.0
cGMP production for ph II and III 10.0
Fill and finish (phII, phIII) 0.7
SPA meeting 0.3
Phase II (a and b) cUTI 6.0
Phase III studies cUTI 30.0
NDA submission 0.3
Total / Year 1.0 1.8 2.1 13.0 14.0 10.0 10.3 52.2
5
9
3
12
6
3
12
18
6
3
3
17
Confidential
Intellectual property
NZ familyWO #
Type Description Issued/priority Expires
10865WO07023163
Composition of matter
Arenicin-3 26.08.2005 26.08.2025
11526WO154525A1
Composition of matter
Arenicin-3 variants 12.06.2010 12.06.2030
11704WO070032A1
Medical use Treatment of UTI with Arenicin-3 11.12.2009 11.12.2029
EP12166275 Medical use Treatment of pneumonia with Arenicin-3 variants
01.05.2012 01.05.2033
18
Broad IP portfolio with composition of matter and method of use patents.
Future patents on specific variants and formulations possible.
Confidential
Competitive Gram-negative antibiotics with novel MoA in
development
Compound Company Develop-ment Target
Spectrum
E.coli Klebsiella Pseudomonas Acinetobacter
Single pathogen
ACHN975 Achaogen PhI LpxC inhibitor ÷ ÷ ÷Pol 7080 Polyphor ltd PhI Membrane modulator ÷ ÷ ÷BioPhage PA BioControl pH2 Undefines
(Virus) ÷ ÷ ÷
IC 43 Novartis ph2 Immunostimulant(Vaccine) ÷ ÷ ÷
KB001 Sanofi Ph2 PcrV inhibitor ÷ ÷ ÷Broad Gram-Negative
GP-4 Trius Preclinical GyrB/ParE RX04 Sanofi Preclinical 50S ribisomal subunit
19
Confidential
Target company Buyer
Upfront Deal Value ($m)
Total Deal Value ($m)
Clinical Stage of
Lead Product
2012 Inhibitex, Inc. Bristol-Myers Squibb Company 2,5002011 Mpex Pharmaceuticals, Inc Aptalis Pharma Inc. 2242011 Inspire Pharmaceuticals, Inc. Merck 4302011 Adolor Cubist 190 4152011 Crucell N.V. Johnson & Johnson 2,2742010 Middlebrook Pharmaceuticals Victory Pharma 17 172009 Prolysis Biota 11 11 Pre-clinical2009 Targanta Therapeutics The Medicines Company 42 1002009 Genelabs Techn. GSK 57 572009 Calixa Cubist 93 403 22009 Novexel AstraZeneca 350 425 2
Antimicrobial deals 2009-2012
20
Confidential
Key Value Drivers for Investment
• Broad spectrum XDR Gram-negative first in class drug with unique MoA and strong patent position
• Significantly increased interest in antimicrobials area with GAIN Act/LPAD introduction
• No new MoA programs in clinical development• Good safety and tox properties and solid in vivo PoC package• Phase II data package to be established for USD 25 mio• Experienced team to execute development plan
21
Confidential
Contact details
Dr Peter NordkildMobile: + 45 25 47 16 46
Email: [email protected]: www.
Adeniumbiotech.com
22